WB ups Selecta Biosciences to outperform

Selecta Biosciences

William Blair upgraded Selecta Biosciences (NASDAQ:SELB) to “outperform,” citing multiple upcoming positive risk/reward catalysts for the company. The stock closed at $3.90 on March 11.

The company’s ImmTOR platform addresses a significant unmet issue with existing adeno-associated virus gene therapies: vector immunogenicity and the ability to re-dose, writes analyst Raju Prasad, Ph.D.

“With the multitude of upcoming gene therapy trials and anticipated growth in the number of trials, we see huge potential for technology that permits re-dosing and enhances the durability of gene therapy,” he said. “In our view, a positive result in gene therapy re-dosing would be a significant catalyst for the shares.”

Dr. Prasad said he anticipates the next 12-to-18 months will be transformational for the company with multiple gene therapy readouts as well as a pivotal trial of SEL-212 in chronic refractory gout.

“Although the results in the Phase 2 COMPARE trial of SEL-212 were numerically superior and SEL-212 has a less frequent dosing schedule (once monthly compared with Krystexxa dosed twice monthly), we believe SEL-212 will likely still be a marketable product,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.